SALIM VIRANI to Proprotein Convertase 9
This is a "connection" page, showing publications SALIM VIRANI has written about Proprotein Convertase 9.
Connection Strength
3.797
-
Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Curr Probl Cardiol. 2022 Jul; 47(7):101043.
Score: 0.724
-
PCSK9 Inhibitors Prior Authorization. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005910.
Score: 0.617
-
Mortality reduction with PCSK9 inhibition: A?case of cautious optimism. J Clin Lipidol. 2019 Sep - Oct; 13(5):712-713.
Score: 0.615
-
Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future. Am J Cardiovasc Drugs. 2025 May; 25(3):293-306.
Score: 0.224
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2024 04; 26(4):119-131.
Score: 0.212
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
Score: 0.208
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023 01; 25(1):31-41.
Score: 0.196
-
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
Score: 0.190
-
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2022 01; 24(1):61-72.
Score: 0.183
-
Highlights of Cardiovascular Disease Studies Presented at the 2021 European Society of Cardiology Congress. Curr Atheroscler Rep. 2021 10 14; 23(12):76.
Score: 0.180
-
Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease. Circ Cardiovasc Qual Outcomes. 2021 09; 14(9):e007237.
Score: 0.178
-
Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
Score: 0.149
-
A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
Score: 0.048
-
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021 06 07; 42(22):2154-2169.
Score: 0.044
-
The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia. Curr Atheroscler Rep. 2015 May; 17(5):508.
Score: 0.029